Int J Biochem Cell Biol. 2017 Apr 27. pii: S1357-2725(17)30088-2. doi: 10.1016/j.biocel.2017.04.010.
[Epub ahead of print]
Abstract
Pathophysiological conditions such as obesity and type 2 diabetes (T2D) are reportedly associated to over-activation of the endocannabinoid system (ECS). Therefore, modulation of the ECS offers potential therapeutic benefits on those diseases. GPR55, the receptor for L-α-lysophosphatidylinositol (LPI) that has also affinity for various cannabinoid ligands, is distributed at the central and peripheral level and it is involved in several physiological processes. This review summarizes the localization and role of GPR55 in tissues that are crucial for the regulation of glucose metabolism, and provides an update on its contribution in obesity and insulin resistance. The therapeutic potential of targeting the GPR55 receptor is also discussed.
Copyright © 2017 Elsevier Ltd. All rights reserved.
KEYWORDS:
endocannabinoids; insulin; islets; obesity
- PMID: 28457969
- DOI: 10.1016/j.biocel.2017.04.010
